Please assess the completion status of the following clinical trial:

Trial Title: Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of invasive bladder cancer~* Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral biopsy (with definitive muscle invasion \> T2) within 4 weeks prior to registration~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* WBC ≥ 3,000/mm\^3~* Neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total bilirubin ≤ 1.5 mg/dL~* Serum creatinine ≤ 1.5 mg/dL~* AST and ALT ≤ 2.5 x upper limit of normal~* Not pregnant~* No liver cirrhosis~* No ischemic cardiovascular disease or arrhythmia for which treatment is necessary~* No cardiac infarction within the past 6 months~* No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen inhalation therapy is needed~* No active cancerous lesion other than upper urinary tract tumor~* No high fever or any other infectious symptom~* No uncontrolled hypertension or diabetes mellitus~PRIOR CONCURRENT THERAPY:~* No prior systemic chemotherapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).